Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Sell
38
CARA Quote, Financials, Valuation and Earnings
Last price:
$5.11
Seasonality move
:
-8.29%
Day range:
$5.09 - $5.29
52-week range:
$2.71 - $11.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.34x
P/B ratio:
33.04x
Volume:
5.5K
Avg. volume:
14.6K
1-year change:
-51.03%
Market cap:
$23.9M
Revenue:
$7.1M
EPS (TTM):
-$15.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
ADMA
ADMA Biologics
|
$112.8M | $0.15 | 41.07% | 75% | $25.27 |
|
NURO
NeuroMetrix
|
-- | -- | -- | -- | -- |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.22 | 16.58% | -42.86% | $17.45 |
|
SRPT
Sarepta Therapeutics
|
$631M | $2.06 | 67.9% | 370.14% | $173.18 |
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$5.23 | $12.00 | $23.9M | -- | $0.00 | 0% | 3.34x |
|
ADMA
ADMA Biologics
|
$20.61 | $25.27 | $4.9B | 25.13x | $0.00 | 0% | 11.74x |
|
NURO
NeuroMetrix
|
$4.39 | -- | $9M | -- | $0.00 | 0% | 2.04x |
|
OCUL
Ocular Therapeutix
|
$7.70 | $17.45 | $1.2B | -- | $0.00 | 0% | 19.12x |
|
SRPT
Sarepta Therapeutics
|
$79.97 | $173.18 | $7.8B | 35.07x | $0.00 | 0% | 4.69x |
|
TGTX
TG Therapeutics
|
$42.47 | $42.83 | $6.7B | 303.36x | $0.00 | 0% | 20.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
-- | -3.732 | -- | 10.67x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
NURO
NeuroMetrix
|
-- | 0.088 | -- | 12.38x |
|
OCUL
Ocular Therapeutix
|
17.85% | 3.384 | 5.09% | 10.26x |
|
SRPT
Sarepta Therapeutics
|
42.67% | 1.259 | 9.65% | 2.74x |
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
NURO
NeuroMetrix
|
$312K | -$1.7M | -41.7% | -41.7% | -296.61% | -$1.8M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
SRPT
Sarepta Therapeutics
|
$526.1M | $161.7M | 10.04% | 20.83% | 26.76% | $54M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Cara Therapeutics vs. Competitors
-
Which has Higher Returns CARA or ADMA?
ADMA Biologics has a net margin of -527.77% compared to Cara Therapeutics's net margin of 95.19%. Cara Therapeutics's return on equity of -374.56% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About CARA or ADMA?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 129.45%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 22.62%. Given that Cara Therapeutics has higher upside potential than ADMA Biologics, analysts believe Cara Therapeutics is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 ADMAADMA Biologics4 0 0 -
Is CARA or ADMA More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock CARA or ADMA?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or ADMA?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Cara Therapeutics's net income of -$7.7M is lower than ADMA Biologics's net income of $111.9M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 25.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.34x versus 11.74x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.34x -- $1.5M -$7.7M ADMAADMA Biologics11.74x 25.13x $117.5M $111.9M
-
Which has Higher Returns CARA or NURO?
NeuroMetrix has a net margin of -527.77% compared to Cara Therapeutics's net margin of -256.8%. Cara Therapeutics's return on equity of -374.56% beat NeuroMetrix's return on equity of -41.7%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M NURONeuroMetrix53.12% -$0.75 $16M -
What do Analysts Say About CARA or NURO?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 129.45%. On the other hand NeuroMetrix has an analysts' consensus of -- which suggests that it could grow by 9014.52%. Given that NeuroMetrix has higher upside potential than Cara Therapeutics, analysts believe NeuroMetrix is more attractive than Cara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 NURONeuroMetrix0 0 0 -
Is CARA or NURO More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison NeuroMetrix has a beta of 2.153, suggesting its more volatile than the S&P 500 by 115.333%.
-
Which is a Better Dividend Stock CARA or NURO?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroMetrix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. NeuroMetrix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or NURO?
Cara Therapeutics quarterly revenues are $1.5M, which are larger than NeuroMetrix quarterly revenues of $587.3K. Cara Therapeutics's net income of -$7.7M is lower than NeuroMetrix's net income of -$1.5M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while NeuroMetrix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.34x versus 2.04x for NeuroMetrix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.34x -- $1.5M -$7.7M NURONeuroMetrix2.04x -- $587.3K -$1.5M
-
Which has Higher Returns CARA or OCUL?
Ocular Therapeutix has a net margin of -527.77% compared to Cara Therapeutics's net margin of -283.27%. Cara Therapeutics's return on equity of -374.56% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About CARA or OCUL?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 129.45%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.45 which suggests that it could grow by 126.68%. Given that Cara Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Cara Therapeutics is more attractive than Ocular Therapeutix.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 OCULOcular Therapeutix5 0 0 -
Is CARA or OCUL More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.
-
Which is a Better Dividend Stock CARA or OCUL?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or OCUL?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than Ocular Therapeutix quarterly revenues of $17.1M. Cara Therapeutics's net income of -$7.7M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.34x versus 19.12x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.34x -- $1.5M -$7.7M OCULOcular Therapeutix19.12x -- $17.1M -$48.4M
-
Which has Higher Returns CARA or SRPT?
Sarepta Therapeutics has a net margin of -527.77% compared to Cara Therapeutics's net margin of 24.16%. Cara Therapeutics's return on equity of -374.56% beat Sarepta Therapeutics's return on equity of 20.83%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M SRPTSarepta Therapeutics79.91% $1.50 $2.7B -
What do Analysts Say About CARA or SRPT?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 129.45%. On the other hand Sarepta Therapeutics has an analysts' consensus of $173.18 which suggests that it could grow by 116.56%. Given that Cara Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Cara Therapeutics is more attractive than Sarepta Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 SRPTSarepta Therapeutics12 2 1 -
Is CARA or SRPT More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.
-
Which is a Better Dividend Stock CARA or SRPT?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or SRPT?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Cara Therapeutics's net income of -$7.7M is lower than Sarepta Therapeutics's net income of $159M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 35.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.34x versus 4.69x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.34x -- $1.5M -$7.7M SRPTSarepta Therapeutics4.69x 35.07x $658.4M $159M
-
Which has Higher Returns CARA or TGTX?
TG Therapeutics has a net margin of -527.77% compared to Cara Therapeutics's net margin of 21.57%. Cara Therapeutics's return on equity of -374.56% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About CARA or TGTX?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 129.45%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 0.86%. Given that Cara Therapeutics has higher upside potential than TG Therapeutics, analysts believe Cara Therapeutics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 TGTXTG Therapeutics5 0 0 -
Is CARA or TGTX More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.
-
Which is a Better Dividend Stock CARA or TGTX?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or TGTX?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Cara Therapeutics's net income of -$7.7M is lower than TG Therapeutics's net income of $23.3M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 303.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.34x versus 20.22x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.34x -- $1.5M -$7.7M TGTXTG Therapeutics20.22x 303.36x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
82
EXOD alert for Mar 20
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
69
SIG alert for Mar 20
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
36
HQY alert for Mar 20
HealthEquity [HQY] is up 0.28% over the past day.
